Alembic Pharmaceuticals Limited

Alchemic Pharmaceuticals Sees USFDA Tentative Approval for Darolutamide, Reports Management Changes & Financial Results

USFDA tentative approval for Alembic’s Darolutamide 300 mg tablets signals a US market launch, while new financial filings and management changes reinforce investor confidence.

Alembic Pharmaceuticals Limited
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

15/05/2026, 11:40

3 minutes to read

Alembic Pharma Reports Q4 2025 Results: 7% Revenue Rise, 18% EBITDA Margin

Discover Alembic Pharmaceuticals’ Q4 2025 unaudited results: 7 % revenue growth, 18 % EBITDA margin, and a 1.5 % share rise—key insights for investors.

Alembic Pharmaceuticals Limited
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

05/02/2026, 10:02

3 minutes to read